[CLINICAL EXPERIENCES WITH A NEW ANTIPARKINSON AGENT, AKINETON, WITH SPECIAL REFERENCE TO EXTRAPYRAMIDAL SYMPTOMS CAUSED BY PHENOTHIAZINE DERIVATIVES].
D000293:Adolescent; D000978:Antiparkinson Agents; D001712:Biperiden; D002493:Central Nervous System Diseases; D002648:Child; D002746:Chlorpromazine; D005116:Extrapyramidal Tracts; D005476:Fluphenazine; D008728:Methotrimeprazine; D010276:Parasympatholytics; D010546:Perphenazine; D010640:Phenothiazines; D012559:Schizophrenia; D014116:Toxicology
D000978:Antiparkinson Agents; D010276:Parasympatholytics; D010640:Phenothiazines; D001712:Biperiden; D008728:Methotrimeprazine; D010546:Perphenazine; D005476:Fluphenazine; D002746:Chlorpromazine
ADOLESCENCE; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHLORPROMAZINE; EXTRAPYRAMIDAL TRACTS; FLUPHENAZINE; METHOTRIMEPRAZINE; PARASYMPATHOLYTICS; PERPHENAZINE; SCHIZOPHRENIA; TOXICOLOGIC REPORT